Status:
ACTIVE_NOT_RECRUITING
Natural History Study of Patients With Neurofibromatosis Type I
Lead Sponsor:
National Cancer Institute (NCI)
Conditions:
Neurofibromatosis Type 1
Malignant Peripheral Nerve Sheath Tumor
Eligibility:
All Genders
4+ years
Brief Summary
Background: Neurofibromatosis Type 1 (NF1) is a genetic disorder in which patients are at increased risk of developing tumors (usually non-cancerous) of the central and peripheral nervous system. The...
Detailed Description
Background Neurofibromatosis Type 1 (NF1) is an autosomal dominant, progressive genetic disorder characterized by diverse clinical manifestations. Patients with NF1 have an increased risk of developi...
Eligibility Criteria
Inclusion
- ELIGIBILITY CRITERIA PATIENT
- INCLUSION CRITERIA:
- Age:
- Less than or equal to 35 years of age for new patients evaluated at NIH.
- No upper age limit for patients previously enrolled on clinical trials at NIH or for patients diagnosed with MPNST, or with clinical concern for MPNST, or with infrequent or unusual NF1 related manifestations.
- Diagnosis: Patients who are diagnosed with NF1 using the NIH Consensus Conference criteria or have a confirmed NF1 mutation with analysis performed in a CLIA-certified laboratory. NF1 mutation testing to confirm eligibility will not be performed on this protocol, but as part of a separate screening study. Histologic confirmation of NF1 related benign tumors is not necessary in the presence of consistent clinical and radiographic findings, but is required for individuals with MPNST who enroll on this study.
- For the clinical diagnosis of NF1 all study subjects must have at least two or more diagnostic criteria for NF1 listed below (NIH Consensus Conference):
- Six or more cafe-au-lait spots (greater than or equal to 0.5 cm in prepubertal subjects or greater than or equal to 1.5 cm in postpubertal subjects).
- Greater than or equal to 2 neurofibromas or 1 plexiform neurofibroma.
- Freckling in the axilla or groin.
- Optic glioma.
- Two or more Lisch nodules.
- A distinctive bony lesion (dysplasia of the sphenoid bone or dysplasia or thinning of long bone cortex).
- A first-degree relative with NF1.
- Prior and current therapy: For NF1 related benign tumor manifestations there is no standard effective medical treatment, and surgery is the only standard treatment. Chemotherapy and radiation therapy are additional treatment options for malignant NF1 related tumors. For the purpose of this study, subjects who have not previously received medical or surgical treatment, patients, who have previously received medical or surgical treatment, and patients who are currently receiving medical treatment and/or radiation for a NF1 related manifestation will be eligible. Prior and current treatment for NF1 related manifestations will be recorded at trial entry and throughout the study.
- Performance Status: ECOG less than or equal to 3. Subjects who are wheelchair bound because of paralysis will be considered ambulatory when they are up in their wheelchair. Subjects have to be able to travel to the NIH for evaluations.
- Informed Consent: All patients or their legal guardians (if the patient is less than 18 years old) must sign an IRB-approved document of informed consent to demonstrate their understanding of the investigational nature and the risks of this study before any protocol-related studies are performed. When appropriate, pediatric subjects will be included in all discussions.
- EXCLUSION CRITERIA:
- In the opinion of the investigator the patient is not able to return for follow-up visits or obtain required follow-up studies.
- In the opinion of the investigator the patient is not able to obtain an MRI scan.
- Individuals who are pregnant or breast feeding or who become pregnant while enrolled on this trial will not be excluded from participation, but will not undergo radiographic evaluations or MRI scans requested for research purposes, or other studies which might negatively impact on the pregnancy.
Exclusion
Key Trial Info
Start Date :
February 25 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
259 Patients enrolled
Trial Details
Trial ID
NCT00924196
Start Date
February 25 2008
Last Update
January 8 2026
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Institutes of Health Clinical Center
Bethesda, Maryland, United States, 20892